



Australian Government

Department of Health, Disability and Ageing  
Therapeutic Goods Administration

## Public Summary

|                                |                                                 |                                       |
|--------------------------------|-------------------------------------------------|---------------------------------------|
| <b>Summary for ARTG Entry:</b> | 298346                                          | BLACKMORES SUPER STRENGTH COQ10 300mg |
| <b>ARTG entry for</b>          | Medicine Listed                                 |                                       |
| <b>Sponsor</b>                 | Blackmores Ltd                                  |                                       |
| <b>Postal Address</b>          | PO Box 1725, WARRIEWOOD, NSW, 2102<br>Australia |                                       |
| <b>ARTG Start Date</b>         | 9/01/2018                                       |                                       |
| <b>Product Category</b>        | Medicine                                        |                                       |
| <b>Status</b>                  | Active                                          |                                       |
| <b>Approval Area</b>           | Listed Medicines                                |                                       |

### Conditions

Colouring agents used in listed medicine for ingestion, other than those listed for export only under section 25 of the Act, shall be only those included in the list of 'Colourings permitted in medicines for oral use'.

The sponsor shall keep records relating to this listed medicine as are necessary to: (a) Expedite recall if necessary of any batch of the listed medicine, (b) Identify the manufacturer(s) of each batch of the listed medicine. Where any part of or step in manufacture in Australia of the listed medicine is sub-contracted to a third party who is not the sponsor, copies of relevant Good Manufacturing Practice agreements relation to such manufacture shall be kept.

The sponsor shall retain records of the distribution of the listed medicine for a period of five years and shall provide the records or copies of the records to the Complementary Medicines Branch, Therapeutic Goods Administration, upon request.

Where a listed medicine is distributed overseas as well as in Australia, product recall or any other regulatory action taken in relation to the medicine outside Australia which has or may have relevance to the quality, safety or efficacy of the goods distributed in Australia, must be notified to the National Manager Therapeutic Goods Administration, immediately the action or information is known to the sponsor.

### Products

#### 1 . BLACKMORES SUPER STRENGTH COQ10 300mg

|                     |                         |                       |           |
|---------------------|-------------------------|-----------------------|-----------|
| <b>Product Type</b> | Single Medicine Product | <b>Effective Date</b> | 2/10/2025 |
|---------------------|-------------------------|-----------------------|-----------|

### Permitted Indications

Antioxidant/Reduce free radicals formed in the body  
Helps reduce/decrease free radical damage to body cells  
Maintain/support energy levels  
Helps in the maintenance of healthy blood lipids/blood fats  
Maintain/support cardiovascular system health  
Maintain/support healthy cardiovascular system function  
Maintain/support heart health  
Maintain/support blood vessel health  
Helps enhance/promote blood vessel health  
Maintain/support (state vitamin/mineral/nutrient) levels in the body

### Indication Requirements

Product presentation must not imply or refer to serious cardiovascular conditions.  
Product presentation must not imply or refer to chronic fatigue syndrome.  
Product presentation must not imply or refer to circulatory disorders/diseases/conditions e.g. thrombosis.  
Product presentation must not imply or refer to lowering blood lipids, blood fats and triglycerides.

### Standard Indications

No Standard Indications included on Record

### Specific Indications

No Specific Indications included on Record

### Warnings

Vitamins can only be of assistance if the dietary vitamin intake is inadequate. OR Vitamin supplements should not replace a balanced diet.  
Do not take while on warfarin therapy without medical advice.

### Additional Product information



Australian Government  
Department of Health, Disability and Ageing  
Therapeutic Goods Administration

| Pack Size/Poison information   |                 |
|--------------------------------|-----------------|
| Pack Size                      | Poison Schedule |
| Components                     |                 |
| 1 . Formulation 1              |                 |
| Dosage Form                    | Capsule, soft   |
| Route of Administration        | Oral            |
| Visual Identification          |                 |
| Active Ingredients             |                 |
| ubidecarenone                  | 300 mg          |
| Other Ingredients (Excipients) |                 |
| Gelatin                        |                 |
| glycerol                       |                 |
| hydrogenated vegetable oil     |                 |
| iron oxide black               |                 |
| iron oxide red                 |                 |
| lecithin                       |                 |
| medium chain triglycerides     |                 |
| purified water                 |                 |
| Soya Oil                       |                 |
| yellow beeswax                 |                 |

© Commonwealth of Australia. This work is copyright. You are not permitted to re-transmit, distribute or commercialise the material without obtaining prior written approval from the Commonwealth. Further details can be found at <http://www.tga.gov.au/about/website-copyright.htm>.

Public Summary